Roche’s Petrelintide Hits 10.7% Weight Loss in Phase II ZUPREME-1 Trial – Amylin Analog Shows Sustained Efficacy Through Week 42

Roche (SWX: ROG, OTCMKTS: RHHBY) announced positive topline results from the Phase II ZUPREME-1 trial evaluating petrelintide in 493 individuals with overweight and obesity (mean BMI 37 kg/m²). Participants achieved up to 10.7% mean weight loss from baseline at week 42 versus 1.7% placebo, demonstrating sustained efficacy for the once-weekly amylin analog acquired through the 2025 Zealand Pharma partnership.

Clinical Trial Results

Drug Profile & Mechanism

Strategic Partnership Context

Competitive Positioning & Market Impact

Development Outlook

• Phase III Design: Head-to-head vs. GLP-1 expected; combination arm with Roche’s internal incretin assets under evaluation
• Combination Strategy: Amylin + GLP-1 co-agonism (tirzepatide-like efficacy with improved tolerability) represents next-generation obesity pharmacotherapy
• Manufacturing: Peptide-based production scalable; Roche’s biologics capacity supports global supply
• Regulatory Pathway: FDA Breakthrough Therapy designation potential given unmet need and novel mechanism

Forward‑Looking Statements
This brief contains forward‑looking statements regarding Phase III development timelines, regulatory pathways, and commercial potential for petrelintide. Actual results may differ due to competitive dynamics, safety findings in larger trials, and reimbursement decisions.-Fineline Info & Tech